Ilka Peters

St. Josef Hospital
Bochum, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Biochemical Early Detection of Postoperative Pancreatic Fistula.

Biochemical Early Detection of Postoperative Pancreatic Fistula.

Journal: Visceral medicine
Published: September 25, 2024

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

Journal: Cancers
Published: July 10, 2024

Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.

Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.

Journal: Cancers
Published: June 21, 2024

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.

Journal: Journal of cancer research and clinical oncology
Published: April 30, 2023

Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.

Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.

Journal: Journal of cancer research and clinical oncology
Published: February 17, 2023

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

Journal: Journal of cellular and molecular medicine
Published: December 14, 2022

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Journal: International journal of molecular sciences
Published: May 26, 2022

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.

Journal: Cancers
Published: April 26, 2022
Showing 1-8 of 8

Last Updated: 09/26/2026